ChemoMetec Forecast, price target & analysts
ChemoMetec Target price 2026 - Analyst rating & recommendation
ChemoMetec Classifications & Recommendation
ChemoMetec Price Target
| Target Price | kr663.00 |
| Price | kr521.50 |
| Potential |
27.13%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target ChemoMetec 2027 .
The average ChemoMetec target price is kr663.00.
This is
27.13%
register free of charge
kr750.75
43.96%
register free of charge
kr555.50
6.52%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend ChemoMetec to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ChemoMetec stock has an average upside potential 2027 of
27.13%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million kr | 495.57 | 531.48 |
| 21.50% | 7.25% | |
| EBITDA Margin | 54.45% | 55.23% |
| 19.29% | 1.43% | |
| Net Margin | 37.62% | 39.52% |
| 12.58% | 5.06% |
5 Analysts have issued a sales forecast ChemoMetec 2026 . The average ChemoMetec sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an ChemoMetec EBITDA forecast 2026. The average ChemoMetec EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 ChemoMetec Analysts have issued a net profit forecast 2026. The average ChemoMetec net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share kr | 10.71 | 12.07 |
| 36.78% | 12.70% | |
| P/E | 41.54 | |
| EV/Sales | 15.62 |
5 Analysts have issued a ChemoMetec forecast for earnings per share. The average ChemoMetec EPS is
This results in the following potential growth metrics and future valuations:
Current ChemoMetec Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | May 17 2026 |
| DNB CARNEGIE |
Locked
➜
Locked
|
Locked | May 07 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Feb 23 2026 |
| DNB CARNEGIE |
Locked
➜
Locked
|
Locked | Feb 06 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Nov 12 2025 |
| DNB CARNEGIE |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| DNB CARNEGIE |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
May 17 2026 |
|
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
May 07 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Feb 23 2026 |
|
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
Feb 06 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Nov 12 2025 |
|
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
May 08 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
